Company Filing History:
Years Active: 2025
Title: Lars Mejnertsen: Innovator in Radiation Therapy Optimization
Introduction
Lars Mejnertsen is a notable inventor based in Sydney, Australia. He has made significant contributions to the field of radiation therapy through his innovative patent. His work focuses on optimizing multi-leaf collimator (MLC) tracking, which is crucial for enhancing the precision of radiation treatments.
Latest Patents
Lars holds a patent titled "Dose-based optimization for multi-leaf collimator ('MLC') tracking during radiation therapy methods and apparatus." This patent describes methods, apparatuses, and systems for dose-based optimization related to MLC tracking during radiation therapy. The method involves calculating a planned radiation dose using an MLC plan in an un-shifted dose volume. It also includes acquiring a target position through motion tracking and shifting the dose volume accordingly. Furthermore, the method integrates a three-dimensional dose into a two-dimensional beam's eye view grid and fits an MLC aperture by minimizing a cost function. The process culminates in calculating and accumulating a delivered dose based on the fitted leaf positions of the MLC and updating the gantry position and MLC leaves for the next planned dose. Lars has 1 patent to his name.
Career Highlights
Lars is affiliated with the University of Sydney Commercial Development & Industry Partnerships. His role at this institution allows him to engage in cutting-edge research and development in the field of radiation therapy. His work is instrumental in advancing treatment methodologies that can significantly improve patient outcomes.
Collaborations
Lars has collaborated with esteemed colleagues such as Paul Keall and Doan Trang Nguyen. Their combined expertise contributes to the innovative solutions being developed in the realm of radiation therapy.
Conclusion
Lars Mejnertsen is a pioneering inventor whose work in radiation therapy optimization is making a meaningful impact in the medical field. His contributions are paving the way for more effective and precise treatment options for patients.